Treatment of advanced esthesioneuroblastoma with high-dose chemotherapy and autologous bone marrow transplantation. A case report

O’Conor, Gregory T.; Drake, Charles R.; Johns, Michael E.; Cail, Wayne S.; Winn, H. Richard; Niskanen, Eero

doi:10.1002/1097-0142(19850115)55:2<347::aid-cncr2820550207>3.0.co;2-n

Cited by 35 publications

(14 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Numerous protocols have been described. [25][26][27]31,45 Favorable responses have been reported with cisplatin-based therapies. 26,45 Furthermore, a prospective study of nine patients using cisplatin and etoposide in combination with stereotactic radiation therapy reported significant clinical responses.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Esthesioneuroblastoma: The Johns Hopkins experience

et al. 2000

View full text Add to dashboard Cite

Background Esthesioneuroblastoma (ENB) is an uncommon malignant neoplasm of the upper nasal cavity. Therapeutic management approaches for this neoplasm lack uniformity and there is no universally accepted staging system. Methods A retrospective review of 27 patients with histologically confirmed ENB managed at The Johns Hopkins Hospital. Results Eighty‐five percent of patients had surgical resection as part of their disease management. Complete surgical resection was achieved in 62% of patients who had a craniofacial resection. Eighty percent of patients with negative surgical margins remain with no evidence of disease, with a median follow‐up of 5.6 years. Adjuvant radiation therapy was beneficial to 62% of patients with positive surgical margins. Clinical responses were observed with cisplatin‐ and etoposide‐containing chemotherapy regimens in patients with advanced disease. A revised staging system based on our experience is proposed. Conclusions ENB is best managed by craniofacial resection with complete tumor resection. Adjuvant radiation therapy is warranted in patients that remain with positive histologic margins of resection. Chemotherapy with cisplatin‐ and etoposide‐containing regimens may be useful for palliation of advanced disease. © 2000 John Wiley & Sons, Inc. Head Neck 22: 550–558, 2000

show abstract

Section: Discussionmentioning

confidence: 99%

“…These include CFR with preoperative or postoperative radiation therapy, CFR with combination radiation therapy and chemotherapy, chemotherapy with radiation therapy, and chemotherapy alone. 13,16,19,[23][24][25][26][27][28][29][30][31] It remains unclear whether combination treatment regimens improve survival over that achieved by CFR alone.…”

mentioning

confidence: 99%

Esthesioneuroblastoma: The Johns Hopkins experience

et al. 2000

View full text Add to dashboard Cite

show abstract

“…93,122 NEUROSURGICAL APPROACHES TO THE ANTERIOR CRANIAL BASE Surgical approaches to the anterior cranial base include transfacial, anterior craniofacial, craniotomy with orbital and/or zygomatic osteotomy, and transsphenoidal. 88,129 The transfacial approaches can be categorized into transoral, transpalatal, lateral rhinotomy, Le Fort I osteotomy, and midfacial degloving.…”

Section: Neurosurg Focus / Volume 12 / May 2002mentioning

confidence: 99%

Tumors of the skull base in children: review of tumor types and management strategies

Tsai¹,

Santoreneos²,

Rutka³

2002

FOC

View full text Add to dashboard Cite

Although many treatment strategies for skull base tumors in adults have been reported, relatively little has been reported regarding such therapies in the pediatric population. Skull base tumors in children present a therapeutic challenge because of their unique pathological composition, the constraints of the maturing skull and brain, and the small size of the patients. In this review, the authors examine the pediatric skull base lesions that occur in the anterior, middle, and posterior cranial base, focusing on unique pediatric tumors such as encepahalocele, fibrous dysplasia, esthesioneuroblastoma, craniopharyngioma, juvenile nasopharyngeal angiofibroma, cholesteatoma, chordoma, chondrosarcoma, and Ewing sarcoma. They review management strategies that include radio- and chemotherapy, as well as surgical approaches with emphasis on the modifications and complications associated with the procedures as they apply in children. Evidence for the advantages and limitations of radiotherapy, chemotherapy, and surgery as it pertains to the pediatric population will be examined. With a working knowledge of skull base anatomy and special considerations of the developing craniofacial skeleton, neurosurgeons can treat skull base lesions in children with acceptable morbidity and mortality rates. Outcomes in this population may be better than those in adults, in part because of the benign histopathology that frequently affects the pediatric skull base, as well as the plasticity of the maturing nervous system.

show abstract

“…A 62% response rate (eight of thirteen patients) to a variety of drugs including vincristine, cyclophosphamide, thiotepa, nitrogen mustard and adriamycin, was reported by Wade (1984). High dose chemotherapy with autologous bone marrow rescue has been successfully utilised for ON (15,21). An improvement in relapse free survival or overall survival for ON is yet to be demonstrated with the use of chemotherapy as an induction agent or in the adjuvant setting.…”

Section: Discussionmentioning

confidence: 99%

Olfactory Neuroblastoma ‐ Management of a rare tumour at the Queensland Radium Institute and literature review

Ahern

Poulsen²

1991

Australasian Radiology

View full text Add to dashboard Cite

Olfactory neuroblastoma (esthesioneuroblastoma) is an extremely rare tumour arising from the olfactory epithelium of the nasal cavity close to the cribriform plate. Most institutions will have little experience in recognising the clinical and histological features, or management of this tumour and reliance is placed on researching the literature when the individual patient presents. This study reviews seven patients with olfactory neuroblastoma treated at the Queensland Radium Institute from 1971 to January 1990. The overall local control rate in this series is 57% (four of seven patients) and 43% of patients (three of seven) remain alive. Conservative surgery and post-operative radiotherapy is recommended for early disease and more radical surgery with post-operative radiotherapy for advanced disease.

show abstract

Treatment of advanced esthesioneuroblastoma with high-dose chemotherapy and autologous bone marrow transplantation. A case report

Cited by 35 publications

References 7 publications

Esthesioneuroblastoma: The Johns Hopkins experience

Esthesioneuroblastoma: The Johns Hopkins experience

Tumors of the skull base in children: review of tumor types and management strategies

Olfactory Neuroblastoma ‐ Management of a rare tumour at the Queensland Radium Institute and literature review

Contact Info

Product

Resources

About